3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of 3B BlackBio Dx Ltd approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, along with the limited review reports from statutory auditors Baheti & Co. On a standalone basis, revenue from operations grew to Rs 2,791.16 lakhs in Q2 FY26 (vs Rs 2,657.79 lakhs in Q2 FY25) and profit after tax rose to Rs 1,494.08 lakhs (vs Rs 1,414.21 lakhs). On a consolidated basis, Q2 revenue was Rs 3,390.21 lakhs and PAT was Rs 1,503.76 lakhs. The company also completed the acquisition of Coris Holding SRL (Belgium) from Avacta Group Plc on August 29, 2025, with Coris consolidated from that date. One-time M&A advisory and due diligence expenses of Rs 54.54 lakhs in Q2 (Rs 138.46 lakhs for the half year) were incurred towards this acquisition.
Healthy revenue and profit growth on both standalone and consolidated basis, supported by the company's strong diagnostic kits segment. The completed Coris acquisition is expected to strengthen the company's international molecular diagnostics footprint and could be a key growth driver going forward.